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Abstract
Background and Aims
Acute liver failure (ALF) is a rapidly progressive heterogeneous illness with high mortality
rate and no widely accessible cure. A promising drug candidate according to previous pre-
clinical studies is the Reg3α (or HIP/PAP) lectin, which alleviates ALF through its free-radi-
cal scavenging activity. Here we study the therapeutic targets of Reg3α in order to gain
information on the nature of the oxidative stress associated with ALF.
Methods
Primary hepatocytes stressed with the reactive oxygen species (ROS) inducers TNFα and
H2O2 were incubated with a recombinant Reg3α protein. ALF was induced in C57BL/6J
mice by an anti-CD95 antibody. Livers and primary hepatocytes were harvested for deoxy-
cholate separation of cellular and extracellular fractions, immunostaining, immunoprecipita-
tion and malondialdehyde assays. Fibrin deposition was studied by immunofluorescence in
frozen liver explants from patients with ALF.
Results
Fibrin deposition occurs during experimental and clinical acute liver injuries. Reg3α bound
the resulting transient fibrin network, accumulated in the inflammatory extracellular matrix
(ECM), greatly reduced extracellular ROS levels, and improved cell viability. Hepatocyte
treatment with ligands of death receptors, e.g. TNFα and Fas, resulted in a twofold increase
of malondialdehyde (MDA) level in the deoxycholate-insoluble fractions. Reg3α treatment
maintained MDA at a level similar to control cells and thereby increased hepatocyte survival
by 35%. No antioxidant effect of Reg3α was noted in the deoxycholate-soluble fractions.
Preventing fibrin network formation with heparin suppressed the prosurvival effect of
Reg3α.
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Conclusions
Reg3α is an ECM-targeted ROS scavenger that binds the fibrin scaffold resulting from he-
patocyte death during ALF. ECM alteration is an important pathogenic factor of ALF and a
relevant target for pharmacotherapy.
Introduction
Acute liver failure (ALF) is a rapidly progressive illness of diverse etiologies characterized by a
massive cell death and a suppression of the regenerative capacity of the liver, often leading to
multi-organ failure [1–3]. Over the last decades, progress in patient care has mostly concerned
intensive care unit protocols and emergency liver transplantation programs [4,5]. No pharma-
ceutical drugs against ALF are available, except for acetaminophen-induced ALF, which is
treatable by a specific antidote, N-acetylcysteine (NAC). The mechanisms of liver cell injury in
ALF are etiology-dependent and involve multiple interconnected death pathways, making it
difficult to identify pertinent therapeutic targets. Hepatocellular oxidative cell death, which is a
shared process among different ALFs, is not well understood, except, to some extent, in the
case of acetaminophen-induced hepatotoxicity [6]. There is indirect evidence that ALF, like
other acute tissue injuries, activates a specific fibrogenesis, different from the common fibrosis
of chronic liver diseases [7–10]. It is widely recognized that the extracellular matrix (ECM)
contains structural and functional proteins that play a key role in the regulation of cellular
function, organization and behavior [11,12]. For example, the ECM glycoprotein fibronectin
has recently been claimed to be a crucial prosurvival factor in ALF [13]. However, extracellular
materials are generally ill protected against oxidation for lack of antioxidants and repair en-
zymes [14,15]. It can therefore be conjectured that the ECM components of liver cells are
strongly oxidized and thus structurally and functionally impaired during ALF. If so, reinforcing
the antioxidant arsenal of the ECM could constitute a new clue guiding the search for anti-ALF
drugs. Here we substantiate this view by demonstrating that the anti-ALF potential of the drug
candidate Reg3α (also known as HIP/PAP) is based on its capability of restoring the function-
ality of the altered ECM. Reg3α is a secreted C-type lectin consisting of a single 16-kDa carbo-
hydrate recognition domain and a NH2-terminal secretion signal. It is part of the intestinal
innate immune system, its interaction with peptidoglycan carbohydrates allowing it to bind
and kill Gram-positive bacteria [16–18]. Moreover, Reg3α is an anti-inflammatory and survival
factor in a variety of eukaryotic cells [19–25] thanks, among other things, to its reactive oxygen
species (ROS) scavenging activity [26].
Materials and Methods
Study approval
Research using human tissues was approved by the review board of the Centre Hépatobiliaire
(Paul-Brousse Hospital, Villejuif). All patients provided written informed consent prior to the
analysis of the retrieved tissues. Human tissue samples were provided by the Biological Re-
source Centre of the Paris-Sud Faculty of Medicine, Villejuif, France (Approval Number: 2011/
39938). Fresh human tissues were obtained after surgical resection by the Pathological Depart-
ment of the Centre Hépatobiliaire (Paul-Brousse Hospital, Villejuif). Tissues were cut in cubes,
put in cryomolds prior to be covered with cryogel and snap frozen in isopenthane/drye ice
(-120°C), and finally stock at -80°C until processing. Freezing time after liver resection was
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about of 30 min when surgery was done at day time, but could go up to 5 hours when surgery
was process at night. Control and ALF samples were processed similarly. The biological and
pathological features of patients involved in this study are summarized in Table 1. Animal
studies were performed in compliance with the institutional and European Union guidelines
for laboratory animal care and approved by the institutional ethics committee (Comité d’Ethi-
que en Experimentation Animal Campus CNRS Orléans C2EA-3).
Recombinant human Reg3α protein
The Reg3α protein was produced in Escherichia coli, purified to99% and released in batches
in compliance with the clinical grade manufacturing process by PX'Therapeutics. It corre-
sponds to the addition of one amino-terminal methionine to the sequence of the secreted (i.e.,
lacking the 26–amino acid signal sequence) form of the human endogenous Reg3α or HIP/
PAP (NP_620355).
Primary hepatocytes
Human hepatocytes were prepared from a lobectomy segment following surgical liver resection
in patients with colorectal cancer metastases. Murine hepatocytes were retrieved from 6-week-
old male C57Bl/6J mice (Charles River, L'Arbresle Cedex, France). Hepatocyte were isolated
following a two-step collagenase method [27] and platted in William’s medium (Life Technolo-
gies, Saint Aubin, France) containing 10% calf serum without collagen coating. Two days later,
cellular death was induced with TNFα/Actinomycin D (20 ng/mL/50 ng/mL) maintained
Table 1. Clinical characteristics of patients involved in the study.
Patient Sex Age Disease Etiology Diagnostic ASAT UI/l ALAT UI/l TP % Time days Management
1 Female 29 ALF Acetaminophen blood analysis 3575 2781 19 6 MARS:NAC
2 Female 58 ALF Acetaminophen FNA 7730 7158 10 2 MARS:NAC
3 Female 38 ALF Acetaminophen FNA 515 626 9 6 MAR-S/NAC
4 Female 18 ALF Acetaminophen blood analysis 2318 4180 15 6 MARS:NAC
5 Female 17 ALF Drug FNA 76 461 24 6 NAC
6 Female 34 ALF Drug FNA 561 589 12 10
7 Female 69 ALF Mushroom blood analysis 2913 4387 21 7 MARS
8 Female 37 ALF HBV Serologic marker 235 1375 11 5 MARS/NAC
9 Female 27 ALF HBV Serologic marker 1530 3020 10 5 NAC
10 Female 68 ALF Autoimmune FNA 762 745 17 29 Vitamin K/Antibiotics
11 Female 65 ALF Autoimmune blood analysis 137 110 20 37 MARS
12 Female 28 ALF Autoimmune FNA 28 1751 8 8
13 Male 41 ALF Undetermined blood analysis 6481 4011 18 3 Antibiotics
14 Female 39 ALF Undetermined FNA 953 631 19 16 MARS/NAC
15 Female 57 ALF Undetermined FNA 823 687 23 30
16 Female 27 ALF Undetermined FNA 269 154 20 69 MARS
17 Female 31 ALF Undetermined FNA 1021 1072 16 90 MARS
18 Male 68 AN 26 25 81
19 Female 68 AN 68 85 87
20 Male 61 AN 24 29 100
ALAT, Alanine Aminotransferase; ALF, Acute Liver Failure; AN, Amyloid neuropathy; ASAT, Aspartate Aminotransferase; FNA, Fine Needle Aspiration;
MARS, Molecular Adsorbent Recirculating System; NAC, N-acetylcysteine; TP, Prothrombin level; Time, time in days from diagnostic to liver
transplantation; UI, International Unit.
doi:10.1371/journal.pone.0125584.t001
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throughout the cell culture or with a 1 mMH2O2 pretreatment for 1 hour. Cell viability studies
were performed under the condition that the cell death rate in stressed control cultures was of
55±10%, a condition easier to fulfill without collagen coating. Hepatocytes were stimulated
with death inducers and 0.24 μMReg3α or an equivalent volume of buffer (vehicle). Cells were
fixed and stained with 5 μg/mL of Hoechst 33342 (Cell Signaling, Ozyme, France). Living and
apoptotic cells were quantified using a Zeiss Axio Imager.M1. Cell quantification was per-
formed on 20 randommicroscopic fields per sample. The normalized cell viability is defined as
(nReg3-nVeh)/(nBas-nVeh), where nReg3, nVeh and nBas are the numbers of living cells in Reg3α-
treated, vehicle-treated and non-intoxicated (basal) cultures at 24h post stress, respectively.
Collagenase type IV, mouse recombinant TNFα, Actinomycin D, H2O2 solution 30%, Heparin,
and MG132 were purchased from Sigma Aldrich.
Murine model of ALF
Six-week-old C57BL/6J mice were maintained for 1 week at 22°C before experiments. ALF was
induced by intravenous injection of an anti-CD95 Fas antibody (BD Pharmigen, Le Pont de
Claix, France) at 170 μg.kg-1, which is a lethal dose for about 60% of the mice within 24 hours.
Reg3α was intravenously injected at the dose of 2.5 mg/kg. The control groups were injected
with equivalent volumes of vehicle. Mice were sacrificed by decerebration and livers harvested
for deoxycholate separation of cellular and extracellular fractions, immunostaining and
malondialdehyde assays.
Real-time qPCR
Total RNA was isolated using TRI reagent (Sigma) according to the manufacturer’s instruc-
tions. Reverse transcription was performed using oligo(dT) primer and 1μg of total RNA in a
final volume of 20 μL with the RevertAid First Strand cDNA Synthesis Kit (Thermo scientific).
Real time qPCR was performed using the FastStart Essential DNA green Master kit (Roche) on
a lightcycler Instrument equipped with the SW 1.1 data analysis software (Roche). Analyses
were done in triplicate. Data were normalized using HPRT as housekeeping gene. Primer se-
quences are: Reg3α forward: 5’-TGGATTGGGCTCCATGACCC-3’OH, Reg3α reverse: 5’-
TTCGGGATGTTTGCTGTCTG-3’OH, HPRT forward: 5’-AGGACCTCTCGAAGTGT-3’OH,
HPRT reverse: 5’-TCAAATCCCTGAAGTACTCAT-3’OH.
Immunoblotting
Primary hepatocyte cultures were washed twice with ice cold phosphate buffered saline (PBS)
and then lysed in a deoxycholate (DOC) lysis buffer containing 2% sodium deoxycholate, pro-
tease inhibitors (cOmplete Protease Inhibitor Cocktail, Roche, Meylan, France), 20 mM Tris-
HCl pH 8.8, 2 mM EDTA, 2 mM iodoacetamide and 2 mMN-ethylmaleimide. The DOC-solu-
ble fractions contain the cellular material and extracellular components that are not incorpo-
rated into the ECM, whereas the DOC-insoluble pellet contains the ECM. Homogenates were
passed three times through a 26-gauge needle, and centrifuged at 10,000 g for 10 min at 4°C.
DOC-insoluble fractions were solubilized in SDS lysis buffer containing 1% SDS sodium dode-
cyl sulphate, 20 mM Tris-HCl pH 8.8, 2 mM EDTA, protease inhibitors, 2 mM iodoacetamide
and 2 mMN-ethylmaleimide. Frozen liver samples were processed in the same way. Protein
concentrations were determined with the Bio-Rad Protein Assay Kit using bovine serum albu-
min as a standard. Aliquots of 30 μg were denaturated by boiling in Tris-Glycine SDS Buffer
(Invitrogen), separated by 12% SDS-PAGE and transferred onto nitrocellulose membranes
(Whatman, Dominique Dutscher, Brumath cedex, France) by electroblotting. Membranes
were blocked in 5% non-fat dry milk in 0.1% Tween 20 Tris-buffered saline for 1h and probed
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with primary antibodies against Fibronectin (Santa Cruz Biotechnology), Fibrinogen (Dako),
Actin (Santa Cruz Biotechnology, Heidelberg, Germany), mouse Reg3β (R&D Systems, Lille
cedex, France), human Reg3α (Santa Cruz Biotechnology) and a lab-made human Reg3α con-
sisting of a rabbit polyclonal antibody raised against the complete Reg3α protein purified by af-
finity chromatography [14].
Immunoprecipitation
Aliquots of 50 μg of proteins from DOC-soluble and insoluble fractions were diluted 1 to 10 in
1%-Triton X-100 nondenaturing lysis buffer (50 mM Tris-HCl pH 7.4, 300 mMNaCl, 5 mM
EDTA, 10 mM iodoacetamide, protease inhibitors) and pre-cleared with 20 μL of protein G
magnetic beads (PureProteome, Millipore, Molsheim, France) for 2 hours at room tempera-
ture. Clarified lysates were incubated with 1 μg of Fibrinogen antibody for 1h at 4°C. The im-
mune complexes were captured using 20 μL of protein G magnetic beads at 4°C for 30min,
purified on magnetic rack, washed four times in 0.1%-Triton X-100 buffer and once in ice cold
PBS. Immune complexes were eluted from magnetic beads in 1X Laemmli loading sample buff-
er and processed for anti-Reg3α immunoblotting.
Immunostaining
Hepatocytes grown on glass coverslip and 4 μm-thick frozen liver sections were fixed in forma-
lin solution (10%, buffered) supplemented with 2% acetic acid for 30 min at room temperature,
which is known to extract fibrinogen, fibrinogen and fibrin degradation product and non-
cross-linked fibrin, thus ensuring that cross-linked fibrin is the major immunoreactant [28].
After fixation, the samples were labeled with primary antibodies (see above) for 45 min at 37°C
and then with secondary (Alexa 488 donkey anti-goat, Alexa 594 donkey anti-rabbit; Life Tech-
nologies) antibodies for 30 min at 37°C. Nuclear DNA was stained with 5 μg/mL Hoechst
33342. Histopathology investigations were performed by microscopic examination of hema-
toxylin/eosin-stained sections of paraffin-embedded tissues.
Lipid peroxidation
Malondialdehyde (MDA) was dosed using the thiobarbituric acid method as previously de-
scribed [26]. A standard curve was prepared using the Malondialdehyde Tetrabutylammonium
Salt (Sigma Aldricht, Lyon, France). The results were normalized in relation to the total
protein content.
Protein carbonylation
Carbonyl groups of 1 μg of DOC insoluble and 10 μg of DOC soluble proteins were derivatized
to 2, 4-dinitrophenylhydrozone (DNP) by reaction with 2,4-dinitrophenylhydrazine in solu-
tion in 2N HCl, incubated 30 min in the dark at room temperature before being precipitated by
addition of an equal volume of 20% trichloroacetic acid. Protein pellets were washed four times
with 1 mL of ethanol/ethyl acetate (1:1), and resuspended in SDS loading buffer. One half of
each sample was analyzed by Western blot using a rabbit anti-DNP antibody while the other
half was resolved on a 10% acrylamide gel for Coomassie blue staining. Amount of carbony-
lated and total proteins were determined by densitometry using the Image J image processing
and analyzing software; results were presented as the ratio of carbonylated on total proteins.
Extracellular ROS Scavenger
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Statistical analysis
Two-tailed Student’s t-test was used to assess statistical differences between groups using Stat-
View 5.0 freeware (SAS Institute, Inc, Cary, North Carolina, USA) and differences with P<0.05
were considered significant. All data are presented as mean over several independent
experiments ± SEM.
Results
The Reg3α lectin binds the extracellular fibrin network of primary human
hepatocytes
We cultured primary human hepatocytes (PHHs), incubated them with 0.24 μM of a recombi-
nant Reg3α protein for 6h and then analyzed Reg3α subcellular distribution by immunofluo-
rescence. Cultured PHHs synthetized an abundant extracellular matrix (ECM) of polymerized
fibrin and fibronectin (Fig 1A and S1A Fig), which covered the entire cell layer 48h after plat-
ting. A similar deposition of a fibrillar matrix in rat hepatocyte cultures was previously reported
[29]. This ECM contained two different fiber networks, one lying on top of the cells and the
other, made of thinner fibers, on the substratum. The Reg3α staining mostly appeared in the
form of small clusters lining the top fibrin-fibronectin network and scattered throughout the
substratum (Fig 1A, S1A and S1B Fig). Incubations performed with fluorescein isothiocyanate
(FITC)-coupled Reg3α yielded a similar Reg3α staining pattern (S1C Fig). We detected some
intracellular staining with the Reg3α antibody in the PHHs cultured with vehicle (Fig 1B,
upper row), which was however essentially nonspecific (Fig 1B, lower row), indicating that the
exogenous Reg3α was not taken up by PHHs. We nevertheless wondered whether a fast prote-
olysis of a taken-up Reg3α had not occurred. A pre-treatment with 10 μM of the proteasome
inhibitor MG132 did not increase Reg3α signal in the soluble fractions of PHHs, discarding
this possibility (S2 Fig). An addition of 50 μg/mL of heparin prevented both extracellular fiber
network formation and Reg3α accumulation in the PHH cultures, demonstrating that the latter
was dependent on the former (Fig 1A and S1A Fig). Deoxycholate-insoluble ECM-enriched
fractions and their correlative soluble cellular fractions were extracted from PHHs cultured ei-
ther with or without Reg3α. The anti-fibrinogen immunoblotting revealed the presence of high
molecular weight (MW) fibrin-fibrinogen complexes and low MW fibrin degradation products
in the insoluble fractions (Fig 1C and S2 Fig). These fractions displayed a strong 16-kDa Reg3α
signal, which was inexistent or weak in the soluble fractions. When the PHHs were treated
with heparin, the insoluble fractions displayed a much-reduced Reg3α signal, confirming that
the binding sites for Reg3α were located on the fibrin fibers. Non-denaturing gel electrophore-
sis showed that Reg3α and fibrin displayed comparable electrophoretic mobility in the insolu-
ble fractions, suggesting that these proteins co-migrated and thus were bound together by a
protein-protein interaction (S3 Fig). Proteins from insoluble and soluble fractions incubated,
or not, with Reg3α and heparin were immunoprecipitated with an anti-fibrinogen antibody
and then analyzed by anti-Reg3α immunoblotting. A strong Reg3α signal was found in the in-
soluble fraction of the PHHs, confirming a protein-protein interaction between Reg3α and fi-
brin (Fig 1D). A relatively strong Reg3α signal was also found in the culture medium of PHHs
with heparin, but not without heparin. This is attributable to the release into the culture medi-
um of residual fibrin fragments interacting with Reg3α following addition of heparin. In other
words, circulating fibrins can interact with, and serve as carriers for Reg3α. We also monitored
the distribution of Reg3α in PHHs stressed with the ROS-inducers TNFα [30] and H2O2. In
the two conditions, a fiber network scattered with Reg3α was observed as early as 2h post incu-
bation (Fig 1E). At longer times post incubation, Reg3α coalesced into large clusters (S1D Fig).
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Fig 1. Reg3α fights oxidative stress to extracellular matrix in vitro. (A and B) Immunofluorescence of
primary human hepatocytes (PHHs) incubated with either a recombinant Reg3α without (A, top) or with
heparin (A, bottom), or (B) vehicle. DNA: blue. (C) Immunoblotting for Reg3α, fibrinogen (Fbg), and
fibronectin (Fn) in DOC-soluble and insoluble extracts from PHHs cultured under the indicated conditions. (D)
Anti-Reg3α immunoblotting (IB) in the indicated fractions of lysates immunoprecipitated (IP) with an anti-
fibrin/fibrinogen antibody. (E) Immunofluorescence of PHHs stressed with H2O2 or TNFα/ActD and treated
either with Reg3α or vehicle. (F) Left: Immunofluorescence of PHHs incubated with heparin and then TNFα/
Extracellular ROS Scavenger
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Reg3α reduces oxidative damage to the extracellular matrix
We studied Reg3α-mediated liver cell viability as a function of the presence, or absence, of an
extracellular fibrin network. Adding Reg3α to TNFα-stressed PHH cultures resulted in a sub-
stantial increase in cell viability, as previously shown [26]. By contrast, an addition of heparin
at the time of cell platting prevented the formation of a fibrin network and totally suppressed
the Reg3α-mediated PHH survival gain (Fig 1F). When heparin was added several hours post
platting, the fibrin network was not altered and the cell survival gain was preserved (S4 Fig).
This underscores the dependence of the cytoprotective effect of Reg3α upon the production of
an extracellular fibrin network. Next we measured the concentration of malondialdehyde
(MDA), an end product of ROS-mediated lipid peroxidation, in the insoluble and soluble frac-
tions of damaged PHHs in the presence, or the absence, of Reg3α and heparin. Stressing PHHs
with TNFα resulted in a significant (about twofold) increase in MDA level in both the soluble
and insoluble fractions. A treatment with Reg3α suppressed the TNFα-induced increase in
MDA level in the insoluble fractions of PHHs, and not in the soluble ones. The anti-oxidant ef-
fect of Reg3α in the insoluble fractions did not occur in PHHs cultured with heparin (Fig 1G).
Globally, these results indicate that Reg3α binds the fibrin-fibrinogen network of PHHs, re-
duces their extracellular oxidative stress and thereby facilitates their survival in
inflammatory environment.
Reg3α is targeted to the hepatic ECM formed during Fas(CD95)-induced
ALF in mice
We studied fibrogenesis and its interaction with Reg3α in a murine model of ALF induced by
the anti-CD95 antibody (Fas). This model is known to be relevant to human viral ALF with mi-
tochondrial damage and ROS overproduction [31,32]. We first looked at whether the fibrin
network developed by primary murine hepatocytes (PMHs) binds human Reg3α. Indeed, we
found that Reg3α accumulated in the form of small clusters on the extracellular fibrin network
in PMHs, like in PHHs (S5A Fig). Immunoblots of the insoluble, fibrin polymer-rich, fractions
of PMH extracts displayed strong monomeric and polymeric Reg3α signals. These were greatly
reduced by a treatment of the PMHs with heparin (S5B Fig). Next, we injected mice intrave-
nously with a single dose of 2.5 mg/kg of Reg3α at different time points after Fas-intoxication
and sacrificed them 2h after Reg3α injection. As controls, we used Fas-intoxicated mice in-
jected with vehicle and healthy mice injected with vehicle or Reg3α. Livers were analyzed by
immunofluorescence and fractions of liver extracts by immunoblotting. We found an extensive
fibrin deposit in the sinusoid spaces of the livers, in agreement with previous reports on drug-
induced ALF in rodents [33–36]. The fibrin deposit increased gradually as the duration of Fas-
intoxication increased, and reached a substantial density from 6h post-Fas (Fig 2A and S6A
Fig). In damaged livers treated with Reg3α, the Reg3α staining remained weak until 4h post-
Fas and became stronger at 6h post-Fas (Fig 2A). Reg3α was co-localized with fibrin (Fig 2B).
We were not able to detect Reg3β, the murine homolog of human Reg3α, in the damaged livers
of Fas-intoxicated mice injected with vehicle (S6A Fig) although we found an activation of the
Reg3β gene by qPCR (S6B Fig). High-MW fibrin bands were detected at 4h post-Fas in the in-
soluble fractions and increased in intensity over time. Reg3α was accumulated in the insoluble
fractions in the same time range (Fig 2C and S7 Fig). This concomitancy suggests that Reg3α
ActD and Reg3α. Right: Normalized cell viability. (G) Normalized concentration of malondialdehyde (MDA) in
DOC-insoluble and DOC-soluble fractions of PHHs subjected to the same treatments as in (F). Scale bars:
50 μm. Student’s t-test, *P < 0.05; **P <0.01.
doi:10.1371/journal.pone.0125584.g001
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Fig 2. Reg3α is targeted to the provisional extracellular matrix of livers injured by the anti-CD95 (Fas) antibody. (A) Immunofluorescence of liver
cryosections frommice intoxicated with Fas for the indicated duration times and injected with Reg3α 2 hours before sacrifice. DNA: blue. Control: healthy
livers. (B) Fibrin-Reg3α double immunostaining at Fas = 8h. (C) Immunoblotting for Reg3α and fibrinogen in DOC-insoluble fractions of livers under the same
conditions as (A). (D) Reg3αwas injected 6 hours post-Fas intoxication. (E) Normalized concentration of malondialdehyde (MDA) and (F) ratio of
carbonylated proteins to total proteins in DOC-insoluble fractions of livers intoxicated with Fas for 6 hours and treated with Reg3α only 30 min before
sacrifice. *P < 0.05, **P < 0.01. Scale bars: 50 μm.
doi:10.1371/journal.pone.0125584.g002
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preferentially binds higher-MW fibrins and defines a time threshold for extracellular accumu-
lation of Reg3α of about 6h in the experimental model under study. It could also explain the
previous observation that an injection of Reg3αmade before 6h post-Fas did not significantly
improve survival and did not attenuate oxidative damage during ALF [26]. In other words, the
therapeutic time threshold for Reg3α corresponded to the time at which its molecular target,
namely, the inflammatory fibrin-fibrinogen matrix, appeared in the course of ALF. The extra-
cellular accumulation of Reg3α continued at longer times during the fibrolytic process con-
comitant with liver repair and regeneration. A strong Reg3α band was still seen in the
immunoblots of insoluble fractions at 24h post-Fas, establishing the stability of Reg3α in the
remodeled ECM (Fig 2D). Finally, a single injection of Reg3α at a time when the fibrin matrix
was abundant (namely, at 6 h post-Fas) sufficed to rapidly reduce the Fas-induced extracellular
oxidative damage: as shown in Fig 2E, the twofold increase in hepatic MDA level due to Fas in-
toxication was suppressed 30 min after Reg3α injection. This result was further validated by
measuring the level of extracellular carbonylated proteins. A massive increase of protein car-
bonylation was noticed 6 h post-Fas, this level was reduced by 40% in animals treated with
Reg3α. This demonstrates that Reg3α can be an effective and fast-acting ECM-associated anti-
oxidant in vivo.
Fibrin deposition in hepatic sinusoids during acute liver failure in humans
According to our findings, the existence of a fibrin-fibrinogen scaffold in the fibrosis associated
with human ALF would be an essential requirement for a pharmacological action of Reg3α.
This has not yet been documented, to our best knowledge. We studied fibrin deposit in frozen
liver explants from 17 patients with ALF of various etiologies (4 acetaminophen-, 2 drug-, 1
mushroom-induced, 2 HBV-, 3 autoimmune-induced ALFs, and 5 ALFs of undetermined ori-
gin) by immunofluorescence. Liver explants from 3 patients with amyloid neuropathy were
used as controls [37]. We found substantial fibrin deposits lining sinusoid spaces within the
areas of hepatocellular necrosis in all the end-stage ALF samples studied, and not in the nor-
mal-liver ones (Fig 3) Seven explants of patients with chronic and malignant disorders were an-
alyzed as a control test. Fibrin deposition was detected in all explants, even non-neoplastic
parenchyma adjacent to tumors (S8 Fig). This supports expectations that exogenous Reg3α
might accumulate on such deposits and thereby act as an ECM-targeted antioxidant in human
ALF and other hepatic disorders.
Discussion
The mechanisms of liver damage and regeneration during ALF are still ill understood. It is gen-
erally accepted that, in case of massive hepatic cytolysis, hepatocytes lose their capacity to re-
generate, and a backup mechanism leading to liver stem cell proliferation/differentiation takes
over. Depending on the cytolysis extension, this second mechanism does not always allow a
fast enough liver repopulation, with for consequence a multi-organ failure and an urgent need
for liver transplantation. During ALF, a number of molecular pathways governing inflamma-
tion and cell death are activated in concert, inducing massive tissue injury and suppressing
liver cell proliferation. The oxidative stress following from a massive—in fact, so massive that it
exceeds the detoxification capacity of the hepatocytes—production of reactive oxygen and ni-
trogen species is presumably an important factor in the pathophysiology of ALF [38]. There is
experimental evidence that ROS are key executers of hepatocyte death, their generation preced-
ing the onset of apoptosis after Fas-induced hepatocyte death [39]. Apoptosis could be pre-
vented by a pre-treatment with the superoxide dismutase mimic (MnTBAP), either on primary
culture of hepatocytes or in the Fas-induced experimental hepatitis mice model [39]. ROS
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modulated hepatocyte death by decreasing FLIP level and by increasing cytochrome C release
in a BID-dependent manner after TNFα- and Fas-induced death receptors activation [40]. In
addition, iron chelation, that prevents the transition from superoxide to hydroxyl radical by
the Fenton reaction, rescued mice from Fas-induced hepatitis [41]. Currently, the unique anti-
dote for acute liver failure is an antioxidant therapy, i.e. continuous intravenous infusion of
NAC, which is recommended by the guidelines to treat patients with acetaminophen poising
[42,43]. NAC is efficient to replenish mitochondrial and cytosolic glutathione within the liver
and to treat the main causes of morbidity in ALF, e.g. multi-organ failure (respiratory distress
syndrome) [44] and sepsis [45]. Recent studies showed that NAC could benefit to patients in-
dependently of glutathione repletion and so be efficient in drug-induced liver injury [46]. Al-
ready, reports of several prospective clinical trials present evidences for its efficacy to treat non-
acetaminophen patients, improving transplant-free survival and serological biomarkers [47–
49]. Despite these great promises, there is place for others antioxidant drugs in the treatment of
ALF as NAC efficiency requires its administration early after the onset of ALF and appears not
to improve transplant-free survival of pediatric non-acetaminophen ALF [50].
This study highlights the pathogenic role of extracellular oxidative stress during ALF and
thus its relevance as a target for pharmacotherapy. This raises the question of the extracellular
sources of ROS that would be involved in experimental and clinical ALFs. Contrary to a wide-
spread opinion, the transport of ROS from intracellular to extracellular compartments is not
necessarily negligible. Some ROS (such as hydrogen peroxide) can diffuse through membranes,
others (such as superoxide) can translocate via carriers (such as VDAC, which is expressed at
Fig 3. Abundant fibrin deposition in human ALFs.Histological analysis using hematoxylin/eosin (H&E)
staining (left), anti-fibrin immunofluorescence (right) of sections of liver explants from patients with end stage
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the plasma membrane, and not only in mitochondria) [51]. Furthermore, extracellular sources
of ROS either originating from the matrix itself or released by necrotic cells exist. It is now
clearly established that tissue injuries release damage-associated molecular pattern (DAMPs)
that activate complement cascade and toll-like receptors [52], both priming macrophages
NADPH oxidase and neutrophils myeloperoxidase [53,54]. Activated macrophages and neu-
trophils generate superoxide and hydrogen peroxide radicals, neutrophils producing also hypo-
chlorous acid. Thus ROS are generated within the extracellular spaces in close contact with
hepatocytes where they can diffuse trough cell membrane to induce cell death [55].
It is known that ECM alteration can dramatically modify not only ECM structure but also
cell fate and function. Many disorders, among which, acute and chronic liver diseases, are asso-
ciated with a strong extracellular oxidative stress. However, the mechanisms connecting ECM
alteration to cell behavior are poorly understood and, from the pharmacological standpoint,
few drugs targeting specific ECM components are available today [56,57]. Here we used the
death receptors TNF and Fas, which induce not only apoptosis, but also necrosis and ROS
overproduction [58], to show that the prosurvival effect of Reg3α-HIP/PAP relied on a strong
antioxidant activity specifically deployed in the stressed ECM of injured liver cells. The extra-
cellular accumulation of Reg3α resulted from its binding to the provisional fibrin deposit that
increased gradually during ALF (Fig 4). In brief, Reg3α is an ECM-targeted antioxidant that
Fig 4. Schematic representation of the mode of action of Reg3α during Fas-induced ALF.Mice were
intoxicated with the anti-CD95 antibody (Fas) and were either untreated (left) or injected intravenously with
2.5 mg/kg of Reg3α at 6h post Fas (right). Two hours later (Fas = 8h), Reg3α is accumulated on the
extracellular fibrin network surrounding stressed hepatocytes, reducing the ROS concentration and
improving cell survival and functionality. At 24h post intoxication, liver regeneration is under way in the
Reg3α–treated mice while the fibrin network is being eliminated by physiologic fibrolysis.
doi:10.1371/journal.pone.0125584.g004
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restores the functionality of ECM components involved in cell fate controlling pathways,
which further studies will have to identify.
To date, liver transplantation is the only recognized therapy of proven benefit against ALF,
except for acetaminophen-induced ALF, which is treatable by NAC. There are methods of liver
support used while waiting for a donor liver or for the native liver to regenerate, but their effec-
tiveness remains unproven and is currently evaluated in multicenter clinical trials [59]. Both
transplantation and liver-support methods require specialized units and expensive complicated
equipment. Therefore, the identification of pharmaceutical therapies would be a major step
forward in the care of patients with ALF. Numerous molecules have been reported to counter-
act ALF by reducing hepatocyte cell death or stimulating liver regeneration during preclinical
studies [2]. A few of them have entered clinical trials, among which a recombinant protein ho-
molog of human Reg3α [26]. The selective targeting of Reg3α to ALF-related acute fibrosis
demonstrated in this study constitutes a pharmacological advantage in terms of both safety
and efficacy. From a therapeutic viewpoint and based on our results, a double-blinded random-
ized phase 2 clinical trial was conducted on patient with non-acetaminophen acute liver failure,
trial that showed significant recovery induced by Reg3α in particular in patients suffering from
autoimmune- and HBV-related acute on chronic liver failure [60]. Finally, it should be noted
that, while the currently explored medical applications of Reg3α are focused on non-acetamin-
ophen-related ALFs, this study suggests that they could conceivably be extended to other he-
patic or non-hepatic inflammatory diseases characterized by an important extracellular
fibrin deposition.
Supporting Information
S1 Fig. Reg3α colocalizes with the fibrin-fibronectin network of primary human hepato-
cytes. (A-C) Primary human hepatocytes (PHHs) were incubated with 0.24 μM of a recombi-
nant Reg3α for 6h either without or with 50 μg/mL of heparin. Control cells were treated with
an equivalent volume of vehicle. (A) Immunofluorescence of Reg3α-treated PHHs either with-
out (middle) or with heparin (bottom). Reg3α: red; Fibrinonectin: green; DNA: blue. Scale bar:
50 μm. (B) Reg3α-fibrin immunostaining focused on either the top of the preparation (left) or
the substratum (right). Reg3α: green; Fibrin: red; DNA: blue. Scale bar: 50 μm. (C) Direct
immunofluorescence using a FITC-coupled Reg3α (Left). Scale bar: 50 μm. IgG: control using
affinity purified IgGs from non-immune rabbit serum (Right). DNA: blue. Scale bar: 100 μm.
(D) Immunofluorescence of PHHs stressed with H2O2 and incubated with Reg3α for the indi-
cated duration times. Reg3α: green. DNA: blue. Scale bar: 50 μm.
(TIF)
S2 Fig. No intracellular Reg3α was detected in Reg3α-treated primary human hepatocytes.
Anti-fibrinogen and anti-Reg3α immunoblotting of the DOC-soluble and insoluble fractions
of Reg3α-treated PHHs cultured either without (basal) or with the proteasome inhibitor
MG132.
(TIF)
S3 Fig. Reg3α and fibrin displayed comparable electrophoretic mobility in the insoluble
fractions. Anti-fibrinogen and anti-Reg3α immunoblotting of the DOC-soluble and insoluble
fractions of Reg3α-treated PHHs. Proteins were resolved on a 12% native discontinuous acryl-
amide gel. Asterisks: bands revealing a co-migration of Reg3α and fibrinogen.
(TIF)
S4 Fig. Heparin does not inhibit the cytoprotective effects of Reg3α. Left: Immunofluores-
cence of PHHs exposed to TNFα/ActD, Reg3α and heparin 48h after platting and then
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incubated for 20h. Reg3α: green. Fibrin: red. DNA: blue. Scale bar: 50 μm. Right: Normalized
cell viability.
(TIF)
S5 Fig. Reg3α binds the extracellular fibrin network of primary murine hepatocytes. Prima-
ry murine hepatocytes (PMHs) were incubated with 0.24 μM of a recombinant Reg3α for 6h ei-
ther without or with 50 μg/mL of heparin. Control cells were treated with an equivalent
volume of vehicle. (A) Anti-Reg3α and anti-fibrin immunofluorescence. Fibrin: red; Reg3α:
green; DNA: blue. Scale bar: 50 μm. (B) Anti-Reg3α and anti-fibrin immunoblotting of DOC-
soluble and insoluble fractions.
(TIF)
S6 Fig. Activation of the murine Reg3 gene during Fas-induced ALF. (A) Immunofluores-
cence of liver cryosections from mice intoxicated with the anti-CD95 antibody (Fas) for the in-
dicated duration times and injected with vehicle 2 hours before sacrifice. Fibrin: red; Reg3α:
green; DNA: blue. Control: Healthy livers. Scale bar: 50 μm. (B) qPCR for the endogenous
Reg3β gene, the murine homolog of Reg3α, in ALF-bearing mice at the indicated times post-
Fas.
(TIF)
S7 Fig. Practically no Reg3α was accumulated in liver DOC-soluble fractions of treated
mice. Anti-Reg3α and anti-fibrinogen immunoblotting in DOC-soluble fractions of liver ex-
tracts from mice intoxicated with the anti-CD95 antibody (Fas) and injected with Reg3α or ve-
hicle at different times post-Fas.
(TIF)
S8 Fig. Fibrin deposition in liver of patients with chronic and malignant disorder. Anti-fi-
brin (red staining) immunofluorescence of cryosections of liver explants from patients with dif-
ferent liver disorders. A: adjacent non-neoplastic cirrhotic tissue; B: non-neoplastic
parenchyma adjacent of gallbladder carcinoma; C: non-neoplastic parenchyma adjacent of
colon cancer metastasis; D: Fibrosis stage F3; E and F: Cirrhosis stage F4. Scale bars: 50 μm.
(TIF)
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